Using Durvalumab for Extensive-Stage Small Cell Lung Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with extensive-stage small cell lung cancer (ES-SCLC) who have previously received durvalumab treatment through an early access program. It aims to gather real-world data on the effectiveness and safety of durvalumab in this patient population. The study will analyze patient outcomes and treatment responses to better understand the potential benefits of durvalumab in managing ES-SCLC. By leveraging data from patients treated in Italy, the study seeks to provide insights into the real-world application of this therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with diagnosis of extensive-stage Small Cell Lung Cancer (ES-SCLC).
2. Patients entered, at least 24 months prior to the study inclusion, the D419QR00007 Early Access Programme (CASPIAN EAP) implemented in Italy.
3. Adult patients (aged ≥ 18 years) at the time of inclusion in the CASPIAN EAP.
4. Patients having performed at least one administration of durvalumab treatment in the CASPIAN EAP.
5. Patients (or their legally acceptable representatives) who have signed the subject informed consent and privacy form, if applicable.

Exclusion Criteria:

1. Patients with unavailable medical chart.

Where it's running

• Research Site
  Bologna, Italy Recruiting
• Research Site
  Catanzaro, Italy Recruiting
• Research Site
  Lucca, Italy Recruiting
• Research Site
  Napoli, Italy Recruiting
• Research Site
  Palermo, Italy Recruiting
• Research Site
  Pistoia, Italy Recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Durvalumab with FLOT before and after surgery for resectable gastric/GEJ cancer in Chinese patients

  This trial tests whether adding durvalumab to FLOT chemotherapy before and after surgery helps Chinese patients with resectable gastric or gastroesophageal junction cancer.

  Recruiting at 11 sites Phase 3 AstraZeneca · Beijing and 40 other locations · NCT07877818

• Zolbetuximab added to FLOT and durvalumab before surgery for CLDN18.2-positive gastric/GEJ cancer

  This study tests whether adding zolbetuximab to FLOT chemotherapy plus durvalumab can improve tumor response before surgery in adults with CLDN18.2-positive gastric or GEJ cancer.

  Recruiting Phase 2 National Cancer Center, Japan · Saitama and 3 other locations · NCT07872722

• Alternating chemo-immunotherapy and FGFR inhibitor for FGFR-positive biliary tract cancer

  This phase 2 trial tests whether alternating gemcitabine/cisplatin with durvalumab and the FGFR2 inhibitor pemigatinib can help people with unresectable or metastatic biliary tract cancers that have FGFR alterations.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07780838

• Durvalumab plus histotripsy for intrahepatic cholangiocarcinoma

  This study tests whether adding histotripsy to ongoing durvalumab helps people with advanced intrahepatic cholangiocarcinoma by boosting the immune response and checking safety.

  Recruiting Phase 2 University of Wisconsin, Madison · Madison, Wisconsin · NCT07766187

• Futibatinib and immunotherapy with chemo as first-line treatment for advanced biliary tract cancer

  A first-line treatment test combines Futibatinib with Zimberelimab and Gemcitabine/Cisplatin to see if it improves survival in people with unresectable or advanced biliary tract cancer.

  Recruiting at 4 sites Phase 3 Taiho Pharmaceutical Co., Ltd. · Brisbane and 20 other locations · NCT07710885

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.